Leriglitazone

Unassigned

New Medicines

Adrenomyeloneuropathy (AMN) in male adults

Information

New molecular entity
Minoryx
Minoryx

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Yes
Yes

Category

Selective PPAR gamma agonist with a superior profile for central nervous system-related diseases; a metabolite of pioglitazone.
X-ALD results in cerebral demyelination, axonal dysfunction in the spinal cord leading to spastic paraplegia, adrenal insufficiency & sometimes testicular insufficiency. X-ALD is the most common peroxisomal disorder with an estimated birth incidence of 1/20,000 (male & female). Male hemizygotes may present with neurological symptoms in 2 forms: X-linked cerebral adrenoleukodystrophy (X-CALD) & adrenomyeloneuropathy (AMN). AMN is characterised by the onset of spastic paraplegia in adult men [1].
Adrenomyeloneuropathy (AMN) in male adults
Oral